MDACC Study No:2007-0835 ( NCT No: NCT00656617)
Title:Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients with High-Risk MDS and AML
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:Cytarabine; Idarubicin; Vorinostat
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest safe dose of
vorinostat that can be given in combination with idarubicin and ara-C for the
treatment of AML and high-risk MDS.

Once the highest safe dose is found, researchers will then try to learn if this
combination treatment can help to control AML and high-risk MDS in newly
diagnosed patients. The safety of this treatment combination will also be
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Cytarabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Initially inpatient for 1 week. After that, as needed.
Supported By:Merck & Co., Inc.
Return Visit:Weekly 1st cycle, then once a month as needed.
Home Care:NA

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults